Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia
Status:
Recruiting
Trial end date:
2023-06-29
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and
efficacy of AGN-241622 ophthalmic solution for the first time in human participants